Skip to main content
main-content

Oncology

ESMO Congress 2019

medwireNews attended ESMO 2019 in Barcelona, Spain.
Watch our expert interviews on the major trials.

Expert interviews from ESMO 2019

02-10-2019 | Gastrointestinal cancer | Video

ESMO 2019: Potential of targeted therapy for cholangiocarcinoma shown in ClarIDHy trial

Ghassan Abou-Alfa takes us through the ClarIDHy results, which suggest that ivosidenib could be an option for IDH1-mutated, advanced cholangiocarcinoma (3:37).

01-10-2019 | Urothelial cancer | Video

ESMO 2019: Atezolizumab shows promise in advanced urothelial cancer

Enrique Grande presents the IMvigor130 trial assessing front-line atezolizumab, either as monotherapy or alongside chemotherapy, in treatment-naïve individuals with locally advanced or metastatic urothelial carcinoma (5:54).

30-09-2019 | Breast cancer | Video

ESMO 2019: KEYNOTE-522 points to pembrolizumab role in triple-negative breast cancer

Peter Schmid discusses data pointing to a role for pembrolizumab in the neoadjuvant and adjuvant treatment of newly diagnosed, early-stage triple-negative breast cancer (3:32).

30-09-2019 | Breast cancer | Video

ESMO 2019: MONALEESA-3 OS results demonstrate ribociclib–fulvestrant benefit

Dennis Slamon outlines the MONALEESA-3 findings showing that postmenopausal women with HR-positive, HER2-negative advanced breast cancer derive a survival advantage from combining the CDK4/6 inhibitor ribociclib with fulvestrant (1:47).

29-09-2019 | Breast cancer | Video

ESMO 2019: MONARCH 2 update – OS gain with abemaciclib plus fulvestrant

George Sledge Jr reports overall survival data for the MONARCH 2 trial investigating the addition of the CDK4/6 inhibitor abemaciclib to fulvestrant in women with HR-positive, HER2-negative metastatic breast cancer (2:49).

29-09-2019 | Gynaecological cancer | Video

ESMO 2019: PAOLA-1 supports maintenance olaparib plus bevacizumab for newly diagnosed advanced ovarian cancer

Adding a PARP inhibitor to maintenance bevacizumab therapy improves progression-free survival for advanced ovarian cancer regardless of BRCA mutation status (1:41).

PROfound paves the way for precision medicine in mCRPC

DNA mutation

Treatment with the PARP inhibitor olaparib improves the outcomes of men with metastatic castration-resistant prostate cancer harboring deleterious mutations in homologous recombination repair genes, show trial results.

IMPACT data support PSA screening in BRCA2 mutation carriers

Blood samples_DNA background

Men with a BRCA2 mutation are more likely to be diagnosed with prostate cancer following annual prostate-specific antigen screening than men without the mutation, interim results from the multinational IMPACT study show.

Notable number of patients taking immune checkpoint inhibitors hospitalized with irAEs

Doctor_hospital bed

Patients receiving immune checkpoint inhibitor treatment have an increased risk for being hospitalized with immune-related adverse events, particularly if they are older or taking combination treatments, researchers report.

Latest news

21-10-2019 | Oncology | News | Article

Treatment-free survival proposed as novel RCC immunotherapy endpoint

Time spent off treatment could be used as a novel clinical trial endpoint for patients undergoing renal cell carcinoma immunotherapy, suggest study findings reported at the ESMO Congress 2019 in Barcelona, Spain.

18-10-2019 | Oncology | News | Article

KEYNOTE-427 updates confirm pembrolizumab benefit for advanced RCC

The latest findings from the KEYNOTE-427 trial add to the efficacy evidence for first-line pembrolizumab against advanced or metastatic renal cell carcinoma regardless of histology.

18-10-2019 | Oncology | News | Article

Electronic nose predicts PD-1 inhibitor response

An electronic nose can predict if patients with advanced non-small-cell lung cancer will respond to immune checkpoint inhibitor therapy by analyzing the composition of volatile organic compounds in patients’ exhaled breath, say researchers.

17-10-2019 | Oncology | News | Article

Neoadjuvant nivolumab tested for metastatic RCC

Results from the ADAPTeR study suggest that giving nivolumab before and after cytoreductive nephrectomy or metastatic biopsy may be a feasible strategy for patients with treatment-naïve metastatic clear cell renal cell carcinoma.

ESMO 2019: Targeted Agent May Improve Survival For IDH1-Mutated Advanced Cholangiocarcinoma

Advanced cholangiocarcinoma patients with an IDH1 mutation may benefit from a targeted therapy

Read the full story on ESMO's oncologyPRO educational website (for registered ESMO members).





Twitter Icon Follow medwireNews

Click here
Image Credits